Monte Rosa Therapeutics Aktie
WKN DE: A3CS44 / ISIN: US61225M1027
|
10.06.2025 13:23:46
|
Monte Rosa Therapeutics Announces IND Clearance Of MRT-8102
(RTTNews) - Monte Rosa Therapeutics, Inc. (GLUE) announced FDA clearance of an Investigational New Drug application for MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory diseases driven by the NLRP3 inflammasome and IL-1. The company plans to initiate a Phase 1 study of MRT-8102 in the coming weeks and expects sharing initial results in first half of 2026.
Monte Rosa is also working to advance a second-generation NEK7 program with enhanced CNS penetration with an IND submission expected in 2026.
Shares of Monte Rosa Therapeutics are up 1% in pre-market trade on Tuesday.
For More Such Health News, visit rttnews.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Monte Rosa Therapeutics Inc Registered Shsmehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Monte Rosa Therapeutics Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
| Monte Rosa Therapeutics Inc Registered Shs | 11,01 | 6,07% |
|